血清生物标志物对头颈部癌症的诊断准确性：一项系统评价与荟萃分析。
Diagnostic accuracy of serum biomarkers for head and neck cancer: A systematic review and meta-analysis.
作者信息
Guerra Eliete Neves Silva, Rêgo Daniela Fortunato, Elias Silvia Taveira, Coletta Ricardo D, Mezzomo Luis André Mendonça, Gozal David, De Luca Canto Graziela
机构信息
Oral Histopathology Laboratory, Health Sciences Faculty, University of Brasília, Brasília, Brazil.
Oral Histopathology Laboratory, Health Sciences Faculty, University of Brasília, Brasília, Brazil.
出版信息
Crit Rev Oncol Hematol. 2016 May;101:93-118. doi: 10.1016/j.critrevonc.2016.03.002. Epub 2016 Mar 4.
Serum biomarkers could be helpful to characterize head and neck squamous cell carcinoma (HNSCC). Thus, the purpose of this systematic review and meta-analysis was to determine the diagnostic capability of serum biomarkers in the assessment of HNSCC patients. Studies were gathered by searching LILACS, PubMed, Science Direct, Scopus and Web of Science up to April 10th, 2015. Studies that focused on serum biomarkers in the diagnosis of HNSCC compared with controls were considered. Sixty-five studies were identified, and the sample size included 9098 subjects. Combined biomarkers demonstrated improved accuracy than those tested individually. Therefore, 12.8% of single and 34.3% of combined indicated that serum biomarkers discriminate patients with HNSCC from controls. The combined biomarkers with better diagnostic capability included Epidermal growth factor receptor (EGFR)+Cyclin D1 and squamous cell cancer-associated antigen (SCCA)+EGFR+Cyclin D1. Beta2-microglobin may also be a promising single biomarker for future studies. Serum biomarkers can be potentially useful in the diagnosis of HNSCC. However, further research is required to validate these biomarkers.
血清生物标志物有助于对头颈部鳞状细胞癌（HNSCC）进行特征描述。因此，本系统评价和荟萃分析的目的是确定血清生物标志物在评估HNSCC患者中的诊断能力。通过检索截至2015年4月10日的LILACS、PubMed、Science Direct、Scopus和科学网收集研究。纳入了与对照组相比聚焦于血清生物标志物在HNSCC诊断中的研究。共识别出65项研究，样本量包括9098名受试者。联合生物标志物比单独检测的生物标志物具有更高的准确性。因此，12.8%的单一生物标志物和34.3%的联合生物标志物表明血清生物标志物可区分HNSCC患者与对照组。具有更好诊断能力的联合生物标志物包括表皮生长因子受体（EGFR）+细胞周期蛋白D1和鳞状细胞癌相关抗原（SCCA）+EGFR+细胞周期蛋白D1。β2-微球蛋白也可能是未来研究中有前景的单一生物标志物。血清生物标志物在HNSCC诊断中可能具有潜在用途。然而，需要进一步研究来验证这些生物标志物。
Zotero 插件